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Abstract
The increase in antibiotic resistance world-wide revitalized the interest in the use of phage lysins to combat pathogenic
bacteria. In this work, we analyzed the specific cleavage sites on the staphylococcal peptidoglycan produced by three phage
lytic proteins. The investigated cell wall lytic enzymes were the endolysin LysH5 derived from the S. aureus bacteriophage
vB_SauS-phi-IPLA88 (phi-IPLA88) and two fusion proteins between lysostaphin and the virion-associated peptidoglycan
hydrolase HydH5 (HydH5SH3b and HydH5Lyso). We determined that all catalytic domains present in these proteins were
active. Additionally, we tested for the emergence of resistant Staphylococcus aureus to any of the three phage lytic proteins
constructs. Resistant S. aureus could not be identified after 10 cycles of bacterial exposure to phage lytic proteins either in
liquid or plate cultures. However, a quick increase in lysostaphin resistance (up to 1000-fold in liquid culture) was observed.
The lack of resistant development supports the use of phage lytic proteins as future therapeutics to treat staphylococcal
infections.
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Introduction
Staphylococcus aureus is a dangerous pathogen responsible for a
variety of infections ranging from skin abscesses to fatal sepsis,
endocarditis, osteomyelitis, septicemia, pneumonia and meningitis
[1]. The emergence of multidrug-resistant strains, especially
methicillin-resistant S. aureus (MRSA) and vancomycin-resistant
S. aureus (VRSA) in nosocomial infections, is raising serious
concerns within the medical community [2,3]. There is thus an
urgent need for novel therapeutic agents directed against this
important pathogen.
Recently, bacteriophages and phage-encoded proteins have
been shown as a feasible alternative to antibiotics to overcome this
problem [4,5]. In particular, two phage encoded peptidoglycan
(PG) hydrolytic activities (endolysins and virion-associated PG
hydrolases) showed antimicrobial activity against Gram-positive
pathogens [5,6]. This has boosted the study of these proteins to be
used as therapeutic agents, particularly in external applications
[7,8]. Multiple studies demonstrate the control of both strepto-
coccal (pneumonia, endocarditis, otitis media, meningitis) and
Bacillus anthracis (intraperitoneal) infections in mice by phage lysins.
These results support the application of endolysins to treat human
and animal infections [7,8]. Noteworthy are the staphylococcal
infections caused by MRSA strains. In this regard, the intraper-
itoneal administration of the endolysin MV-L from phage
phiMR11 protected mice against MRSA septic death [9]. Similar
results were obtained with LysGH15 since the intraperitoneal
administration of the lytic enzyme 30 min after MRSA infection
was sufficient to guarantee survival of the mice for up to 60 days
after treatment [10].
Endolysins and PG hydrolases in general, target the cell wall of
both Gram-positive and Gram-negative bacteria, where they
cleave covalent bonds. S. aureus PG is a complex molecule
composed of a sugar backbone of alternating N-acetylglucosamine
and N-acetyl muramic acid residues coupled by b (1R4) linkages.
The glycan polymer is in turn linked covalently to short stem
peptides which are cross-linked to opposite stem peptides via a
pentaglycine (Gly5) bridge generating a three-dimensional net-
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work that surrounds the staphylococcal cell [11]. In some genera
like Staphylococcus, endolysins have evolved acquiring multiple
catalytic domains, which confer certain substrate specificities [12].
However, for most of endolysins described to date no biochemical
data confirming activity on PG for these domains are available.
The main advantage in the use of endolysins as antimicrobials is
the non-detection of bacterial resistance after their repetitive use.
Bacterial strains resistant to phage endolysins have not been
reported to date, despite efforts to find them. Repeated exposure
of Streptococcus pneumoniae to lysin Pal [13] and B. anthracis to lysin
PlyG [14] did not result in the development of lysin-resistant
bacteria. In S. pneumoniae, the absence of resistance was associated
with the presence of choline as a cell wall component essential for
pneumococcal viability, which acts at the same time as receptor for
the lytic enzymes [15].
The endolysin LysH5 (481 amino acids) encoded by phage
vB_SauS-phiIPLA88 (phiIPLA88) was previously characterized
and determined by homology to have three putative domains, an
N-terminal cysteine, histidine-dependent amidohydrolases/pepti-
dase (CHAP) domain, an amidase-2 domain, and a C-terminal
SH3b cell wall-binding (CWB) domain (Fig. 1A). LysH5 is able to
inhibit S. aureus growth in milk [16] and shows a synergistic
antimicrobial effect with the bacteriocin nisin [17].
The phage phiIPLA88 virion-associated PG hydrolase (HydH5)
was also characterized [18]. By homology screening, it was shown
that HydH5 (634 amino acids) has an N-terminal CHAP lytic
domain and a C-terminal LYZ2 (lysozyme subfamily 2) lytic
domain. An apparent cell wall binding domain was not identified.
By combination between lysostaphin and HydH5 domains, fusion
proteins (HydH5SH3b and HydH5Lyso) were obtained (Fig. 1A).
These proteins exhibited high lytic activity against bovine and
human S. aureus, methicillin resistant S. aureus N315 and human
Staphylococcus epidermidis strains [19]. A synergistic interaction
between these fusion proteins and phiIPLA88 endolysin LysH5
was also observed [19].
In order to perform an in deep characterization of these phage
derived proteins, we studied the catalytic activity of the domains
included in LysH5, HydH5SH3b and HydH5Lyso by mass
spectrometry analysis of the specific cleavage sites in the S. aureus
PG. We also evaluated the potential of these phage derived
proteins as therapeutic agents through measure of the staphylo-
coccal resistance development after repeated exposure to them.
Materials and Methods
Bacterial Strains and Culture Conditions
S. aureus Sa9 was used as indicator strain for lytic activity [16]
and routinely cultivated either in TSB broth (Tryptic Soy Broth,
Difco, Franklin Lakes, NJ) at 37uC with shaking or in TSB plates
containing 2% (w/v) bacteriological agar (TSA).
Protein Expression and Purification
Expression and purification of LysH5, and HydH5SH3b and
HydH5Lyso were performed as previously described [17,19].
Lysostaphin was obtained from Sigma (Sigma, Missouri, USA).
Lytic activity quantification of the purified proteins was performed
by turbidity reduction assays against live S. aureus Sa9 cells as
previously described [16,19].
Determination of Proteins Cleavage Sites in the PG
Purified PG (2 mg) of S. aureus SA113 (CeCo Labs, Tu¨bingen,
Germany) was incubated overnight at 37uC with 1 mM of
HydH5SH3b or HydH5Lyso in a final volume of 250 ml activity
buffer A: HEPES 50 mM, NDSB-201(non detergent sulfobetaine)
0.5 M, CaCl2 0.25 mM, MnCl2 0.25 mM, MgCl2 0.25 mM,
TCEP (tris(2-carboxyethyl)phosphine) 1 mM, NaCl 24 mM, KCl
1 mM pH 7.5. Similar digests of PG with LysH5 were performed
in phosphate buffered saline (PBS). Samples were boiled 3 min to
stop the reaction and centrifuged at 14,0006g for 5 min to
eliminate the insoluble fraction. Soluble muropeptides obtained in
each digestion were separated by reverse-phase HPLC using a
Nucleosil 100 column (C18; 12564.6 mm; 5 mm; Maisch GmbH,
Ammerbuch, Germany) and a water/0.1% TFA: 80% acetoni-
trile/0.1% TFA gradient for 150 min at flow rate of 0.5 ml/min.
Peaks were then analysed by Liquid Chromatography-Mass
Spectrometry (LC-MS) (Agilent Technologies, Waldbronn, Ger-
many).
Determination of Bacterial Resistance to Lytic Proteins
Resistant development was tested using repeated exposures in
both the plate lysis and the minimal inhibitory concentration
(MIC) assays. For the plate lysis assay, 2-fold serial dilutions of the
proteins were spotted (10 ml) onto a freshly plated lawn of S. aureus
Sa9 on TSA plates and grown overnight at 37uC. LysH5 dilutions
were made in activity buffer B (CHES 50 mM, PEG 3350 0.06%,
CaCl2 0.25 mM, MnCl2 0.25 mM, ZnCl2 0.25 mM, TCEP
1 mM, pH 9), starting at 1 mM. HydH5SH3 and HydH5Lyso
dilutions were made in activity buffer A starting at 4 mM and
lysostaphin dilutions were made in activity buffer A starting at
1 mM. Cells from spots with a not fully cleared lawn (sub-lethal)
were scraped, inoculated in 5 ml of TSB and grown to mid log
phase (OD600nm 0.4–0.6) to generate a new lawn for the next
round of plating and enzyme exposure. After 10 rounds of
exposure, cells were grown for 5 additional overnight cultures on
TSA plates in the absence of lytic proteins to allow any putative
phenotype-reversion of non-genetically altered strains. Finally, a
new plate lysis assay was performed with the cultures resulting
from these 5 non-selective grow-outs to re-test the sensitivity of the
putative resistant cultures to the lytic proteins.
In the MIC assays, for 10 consecutive days, cells were exposed
overnight to 2-fold serial dilutions of LysH5, HydH5SH3b,
HydH5Lyso and lysostaphin. MICs were performed as previously
described [20] using S. aureus Sa9 strain. Proteins concentrations
started at 0.25 mM for lysostaphin and LysH5 and 3 mM for
HydH5SH3b and HydH5Lyso. In every round, 100 ml of the first
well with growth (K MIC) were inoculated into 5 ml of TSB and
grown to mid log phase (DO600nm 0.4–0.6). These cultures were
used for the next round of MIC exposure. Cells surviving after
round 10 were grown for 5 additional rounds in TSB without lytic
proteins to allow phenotype-reversion; then, MICs were per-
formed to measure the sensitivity to the proteins after non-selective
grow out.
Results
Identification of the PG Bond Cleaved by Phage Lytic
Proteins
To determine the LysH5, HydH5SH3b and HydH5Lyso PG
cut sites, LC-MS was performed on proteins-digested S. aureus PG
preparations. The LysH5 digestion generated a primary product
which in MS yields a peak with m/z = 702.5 (Fig. 2A), a
measurement that is in close agreement with the structure of the
PG cleavage fragment NH2-L-Ala-D-iGln-L-Lys-(NH2-Gly5)-D-
Ala-COOH (calculated MH+702.41). To generate this fragment,
two enzymatic activities must be present, an amidase that cleaves
between the N-acetylmuramic acid and L-alanine of the stem
peptide, and an endopeptidase that cleaves either at the termini or
within the pentaglycine cross-bridge. Identical MS spectra were
Cleavage Sites of Phage Lytic Proteins
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obtain for phi11 endolysin (97% homologous to LysH5) which was
determined to have both a N-acetylmuramoyl-L-alanine amidase
and an endopeptidase activity that cleaves at the termini of the
cross-bridge between the last Gly and the D-Ala (Fig. 3) [11].
HydH5SH3b S. aureus cell wall digestions gave a predominant
peak which yielded an ion in MS with m/z 1180.7 (Fig. 2B). The
peak ion mass corresponds to the PG fragment with structure
MurNAc-(L-Ala-D-iGln-L-Lys-(NH2-Gly5)-D-Ala-COOH)-(b-1–
4)-GlcNAc. Consistent with the two lytic domains identified in
HydH5 via homology screening (Fig. 1A), two enzymatic activities
are needed to generate this fragment, a muramidase activity to
cleave the sugar backbone, and an endopeptidase activity to cleave
the interpeptide cross-bridge. The exact cleavage site of the
endopeptidase is not obvious, in so far as a consistent cleavage site
anywhere in the pentaglycine bridge would generate a fragment
with 5 Gly residues. However, the presence of multiple smaller
peaks (m/z 1123.6, 1066.6 and 1009.6) that differ in size in one
Gly residue, suggests that the endopeptidase does have a preferred
cleavage site (largest peak) but might be promiscuous and cleave at
multiple Gly-Gly bonds in the interpeptide bridge.
PG digestions with the HydH5Lyso fusion (Fig. 2C) yields a
peak ion at m/z 1123.6 which corresponds closely to a PG
fragment consisting of MurNAc- (L-Ala-D-iGln-L-Lys-(NH2-
Gly4)-D-Ala-COOH)-(b-1–4)-GlcNAc indicating that both the
endopeptidase and muramidase domains are active in this
construct. However, one smaller peak (m/z 1066.6) is also
produced. This peak differs in size from the larger peak in one
Gly residue. The loss of one Gly residue suggests that the HydH5
endopeptidase is also active in this construct and likely can cleave
between Gly residues 1 and 2 or 4 and 5. Further evidence of the
cleavage sites comes from MS/MS of the HydH5SH3b PG
digestion product m/z = 1180.7 ion which yielded two major
fragmentation product ions at m/z = 774.5 and m/z= 959.5
(Fig. 4A). The m/z= 959.5 ion corresponds to the MurNAc- (L-
Figure 1. Modular organization and resistance development of lytic enzymes. A) Modular organization of lytic enzymes containing one
(lysostaphin), two (LysH5 and HydH5SH3b) or three (HydH5Lyso) catalytic domains. Large black box: endopeptidase domain; Diagonal stripes: SH3b
domain; Grey box: CHAP domain; Black dots: amidase-2 domain; Horizontal stripes: LYZ2 domain. Homology: 54% between LysH5 SH3b and
Lysostaphin SH3b domains; 30% between LysH5 CHAP and HydH5 CHAP domains. B) Resistance development in solid medium. Plate lysis method
using 1:2 serial dilutions of each protein spotted onto a S. aureus Sa9 lawn. C) Resistance development in liquid medium. Minimal Inhibitory
Concentration (MIC) repeated exposure assay using 1:2 serial dilutions of each protein added to 56105 CFU/well of S. aureus Sa9. In both assays, cells
surviving atK MIC were used as an inoculum for each subsequent round of exposure. The change in susceptibility is presented as fold change from
day 1 to 10 of exposure. Error bars are the means 6 standard deviations of two independent assays.
doi:10.1371/journal.pone.0064671.g001
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Ala-D-iGln-L-Lys-(NH2-Gly5)-D-Ala-COOH)-(b-1–4)- GlcNAc,
whereas the compound with the m/z = 774.5 is in agreement with
the PG structure MurNAc-(L-Ala-D-iGln-L-Lys-(NH2-Gly3), sug-
gesting that the remaining 2 Gly residues in the PG fragment are
linked to the D-Ala at position four in the stem peptide. This may
indicate that the CHAP domain of HydH5SH3b cleaves the bond
between Gly residues at positions 3 and 4 of the cross-bridge
peptide (Fig. 3). Nevertheless, this could be the preferred cleavage
site, as other smaller peaks of the digestion yielded ions with m/z
1123.6, 1066.6 and 1009.6 corresponding to similar PG fragments
with 4, 3, and 2 Gly residues (Fig. 2B), respectively, and ions with
m/z 1237.7, 1294.7 and 1351.7 corresponding with 6, 7 and
8 Gly, respectively (data not shown). These data suggest that the
HydH5 CHAP domain is a glycyl-glycine endopeptidase that
cleaves any Gly-Gly bond of the pentaglycine cross-bridge, with a
preferential site between the third and fourth Gly residues. MS/
MS of the m/z = 1123.6 ion, the main product of the S. aureus PG
digestion with HydH5Lyso, yielded two main ‘daughter ions’ with
m/z 717.5 and 902.5 (Fig. 4B). The m/z 902.5 ion corresponds to
the product of the removal of the GlcNAc in the structure
MurNAc- (L-Ala-D-iGln-L-Lys-(NH2-Gly4)-D-Ala-COOH)-(b-1–
4)- GlcNAc, and m/z 717.5 ion corresponds to the PG structure
MurNAc-(L-Ala-D-iGln-L-Lys-(NH2-Gly2), indicating, as previ-
ously, that 2 Gly residues in the MurNAc-(L-Ala-D-iGln-L-Lys-
(NH2-Gly4)-D-Ala-COOH)-(b-1–4)- GlcNAc ion are likely linked
to the terminal D-Ala of the stem peptide. These data suggest that
the glycyl-glycine bond between Gly residues 2 and 3 of the
interpeptide bridge were likely cut by the lysostaphin endopepti-
dase domain of HydH5Lyso (Fig. 3), since the preferred cleavage
site for the CHAP endopeptidase domain is between Gly 3 and 4
as described above for HydH5SH3b.
Assessment of S. aureus Resistance to Phage Lytic
Proteins
In order to assess the ability of S. aureus to develop resistance
against phage lytic proteins, we initially attempted to select
mutants by serial subculture of S. aureus Sa9 in the presence of sub-
inhibitory concentrations of proteins LysH5, HydH5SH3b,
HydH5Lyso. Exposure of S. aureus Sa9 to lysostaphin was used
as a positive control for resistance development. In two
Figure 2. MS analysis, in positive mode, of the overnight digestion of 2 mg of S. aureus SA113 peptidoglycan with phage lytic
proteins. Peptidoglycan was digested using 1 mM of: A) LysH5, B) HydH5SH3b and C) HydH5Lyso in a final volume of 250 ml buffer HEPES 50 mM,
NDSB-201 0.5 M, CaCl2 0.25 mM, MnCl2 0.25 mM, MgCl2 0.25 mM, TCEP 1 mM, NaCl 24 mM, KCl 1 mM pH 7.5 for HydH5SH3b and HydH5Lyso and
phosphate buffered saline (PBS) for LysH5. The primary products obtained are indicated.
doi:10.1371/journal.pone.0064671.g002
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independent subcultures in which the plate lysis method was used,
the concentration of lysostaphin that produced a cleared spot
increased from 0.0360.0 mM to 361.4 mM at the end of the
experiment; a ,100-fold rise in resistance (Fig. 1B). In contrast,
when S. aureus Sa9 was exposed to serial dilutions of LysH5,
HydH5SH3b and HydH5Lyso, no spontaneous resistant mutants
were recovered. Confirmation of this result was obtained by serial
subculture in liquid medium in the presence of sub-inhibitory
concentrations of these proteins (MIC assay). The lysostaphin
MIC increased ,1000-fold (from 0.00360.0 mM to 361.4 mM)
after 10 rounds of exposure (Fig. 1C), whereas serial subculture in
liquid medium failed to select resistant variants for LysH5,
HydH5SH3b and HydH5Lyso. Noteworthy is the differential
stability of lysostaphin resistance in both assays. A remarkable
decrease in resistance was observed for isolates derived from liquid
culture in the absence of lysostaphin (Fig. 1C) as opposed to a
higher stability observed from solid medium-derived mutants
(Fig. 1B).
Discussion
The molecular structure of some phage lytic proteins composed
by several catalytic domains seems to be a strategy to guarantee
their biological function [12]. We have previously demonstrated
that phage lytic proteins from bacteriophage phiIPLA88 are highly
effective in the elimination of S. aureus strains [16,18,19]. In the
work presented here, the analysis of PG cut sites for these proteins
indicated that all predicted catalytic domains are active. However,
the ability to digest purified PG might not reflect the activity on
live cells [20]. This is not expected to be the case for HydH5 since
the CHAP and LYZ2 domains, as single domains obtained via
deletion analysis, have shown similar lytic activity on live cells
[18,19]. This similar activity of both domains contradicts the
results previously reported by other authors since one of the two
catalytic domains seems to be almost inactive in some modular
endolysins [20–23]. Similarly, the lysostaphin endopeptidase
domain is active in the triple-lytic domain fusion HydH5Lyso, as
the specific activity of this construct on live cells is higher than that
previously obtained for HydH5SH3b [19].
Our results indicate that CHAP and lysostaphin endopeptidase
domains have some overlap in their target bonds. However, we
have a conclusive proof of the fully activity of the lysostaphin
domain at the C-terminus of the fusion construct which is
consistent with the C-terminal position of lysostaphin in a
previously reported triple fusion [24]. On the other hand, it was
unexpected that the HydH5 CHAP domain would be a glycyl-
glycine endopeptidase since other CHAP domains from staphy-
lococcal lysins were reported to be alanyl-glicine endopeptidases
[11]. However, mass spectrometry data clearly indicate CHAP
domain activity which is supported by the N-terminal position of
this domain in the fusion construct (i.e. the same as the native
HydH5 protein). Moreover, it is interesting to speculate about the
activity of this domain against the classical lysostaphin resistant
mutants. Furthermore, the presence of an active LYZ2 domain in
the chimeric proteins ensures that this fusion protein will confer
antimicrobial activity despite any alteration of the pentaglycine
interpeptide bridge.
Development of bacterial resistance is a major issue that should
be addressed before implementation of new antimicrobials. We
have determined that resistance to the phage lytic proteins LysH5,
HydH5SH3b and HydH5Lyso seems to be a rare event as
deduced from the absence of S. aureus spontaneous mutants able to
survive after repeated exposures to the proteins. These results are
in concordance with previous studies about endolysins resistance
development in which no bacteria resistant to streptococcal phage
endolysins were found despite several attempts to find them [25].
It has been hypothesized that phage lytic enzymes have evolved to
target essential bonds in the cell wall, making resistance to these
enzymes unlikely [26]. Furthermore, the high-affinity binding of
some endolysins is directed towards species- or strain-specific cell-
wall carbohydrates that are often essential for viability. This is the
case of amidases PlyG whose specificity for specific bacilli is
achieved by selective binding to a uniquely galactosylated core
structure [27], and Pal which contains a choline binding module
that attaches the enzyme to choline residues present in pneumo-
coccal envelope [28]. Having so conserved catalytic and binding
targets could be a reason for the lack of bacterial resistance
development against these phage proteins [13,14].
On the other hand, bacterial resistance is less likely in response
to dual acting lysins compared to single lytic domains lysins [26]
due to the need to modify multiple target cleavage sites. Similarly,
three active domains are likely to further prevent resistance
development [24]. Phage lytic proteins LysH5, HydH5SH3b and
HydH5Lyso are endowed of multiple catalytic domains active
against both highly conserved (LysH5 amidase domain, HydH5
lysozyme domain) and less conserved bonds (LysH5 CHAP
domain, HydH5 CHAP domain). Thus, HydH5 CHAP domain
cleaves the pentaglycine bridge which in the case of S. aureus is
easily modified, as shown in mutants that avoid the action of
lysostaphin [29]. Maybe that modification could also hamper
HydH5 CHAP activity; however, the presence of an additional
active muramidase domain (LYZ2) in HydH5 can ensure the
antimicrobial activity of the protein. In this regard, we could not
state to what extent the lack of resistance for these phage lytic
proteins was due to the presence of multiple catalytic domains or
to the addition of activities against high conserved bonds, or both.
Conclusions
Phage lytic proteins have a potential use as antistaphylococcal
agents for treatment of infections caused by S. aureus antibiotic-
Figure 3. HydH5SH3b and HydH5Lyso cleavage sites on the
peptidoglycan structure of S. aureus. The glycan chain consists of
b- 1,4- linked monomers of N-acetyl glucosamine (GlcNAc) and N-acetyl
muramic acid (MurNAc). The stem peptide contains amino acids L-Ala,
D-iGln, L-Lys and D-Ala. This peptide is cross-linked to an opposite stem
peptide on a separate glycan polymer through a pentaglycine (Gly5)
interpeptide bridge. Arrows indicate the bonds targeted by the lytic
proteins.
doi:10.1371/journal.pone.0064671.g003
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resistant strains and as biocontrol agents in the food industry.
Therefore, prior to their use we proved the activity of all their
catalytic domains and the lack of resistance development after
repeated exposure of S. aureus to sub-inhibitory concentrations of
LysH5, HydH5SH3b and HydH5Lyso.
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